Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMGX-102
- Development stage
- Preclinical
- Lead developer
- Novus Biologicals
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
IMGX-102 is a bispecific nanobody therapeutic candidate currently in preclinical development by IMGENEX for the treatment of oral cancer. The molecule is engineered to simultaneously target and neutralize Vascular Endothelial Growth Factor (VEGF) and the Epidermal Growth Factor Receptor (EGFR). By dual-targeting these pathways, IMGX-102 is intended to inhibit VEGF-driven angiogenesis and EGFR-mediated tumor cell proliferation and survival signaling. This combinatorial approach aims to overcome resistance mechanisms often associated with single-agent therapies in head and neck squamous cell carcinomas, including oral cancer. As of 2024, the program is listed in the sponsor's therapeutics pipeline at the preclinical stage.
02
Targets
Beyond the preview
Go deeper on IMGX-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMGX-102.